UBS confirms its buy recommendation on the stock and raises its price target to E785 (from E770), which represents a potential upside of 21% compared with the current price/

. The analyst notes an inflection point in future orders. ' ASML remains our best choice for 2024 ' says UBS.

Recall that the group has announced the revocation of an export license by the Dutch government, which has impacted a small number of customers in China.

' We do not expect the current revocation of our export license or the latest US export control restrictions to have a material impact on our financial outlook for 2023 ' said the group.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.